The New Biosimilar of Infliximab SB2 Can be Quantified by IFX-Optimized Therapeutic Drug Monitoring Assays

BÜHLMANN Quantum Blue® Infliximab Citation:

Magro, F., Rocha, C. et al. P229 The new biosimilar of infliximab SB2 can be quantified by IFX-optimized therapeutic drug monitoring assays.  Journal of Crohns and Colitis.  2018, Jan. DOI: 10.1093/ecco-jcc/jjx180.356.

BÜHLMANN Quantum Blue® Infliximab is for Research Use Only in the US.  Not for use in diagnostic procedures in the US.

Health Canada License: 98838